At a glance
- Originator Watson Laboratories
- Developer AbbVie
- Class Antihyperlipidaemics; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Hypercholesterolaemia; Hypertriglyceridaemia
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Dec 2018 Rosuvastatin zinc is not yet available in USA for Hypercholesterolaemia and Hypertriglyceridaemia indications (Allergan website, November 2018)